Current Trials & Studies
Study nameStudy TitleStudy TypeSponsorSponsor Type
Redefine 2"Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes" Clinical Trial (NCT05394519)Novo NordiskCommercial: Industry
Redefine 3 The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease Clinical Trial (NCT05669755)Novo NordiskCommercial: Industry